Hainan Shuangcheng Pharmaceuticals Co., Ltd.
SZSE:002693.SZ
6.85 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 174.206 | 235.93 | 274.754 | 320.294 | 269.442 | 346.649 | 337.243 | 246.77 | 145.136 | 230.97 | 161.198 | 149.605 | 129.664 | 133.503 | 112.877 | 88.183 |
| Cost of Revenue
| 76.586 | 82.41 | 88.288 | 81.388 | 60.182 | 95.105 | 120.856 | 91.457 | 69.932 | 102.135 | 55.92 | 52.767 | 37.138 | 33.695 | 28.35 | 28.941 |
| Gross Profit
| 97.62 | 153.52 | 186.466 | 238.905 | 209.26 | 251.544 | 216.387 | 155.312 | 75.204 | 128.835 | 105.278 | 96.837 | 92.526 | 99.808 | 84.527 | 59.242 |
| Gross Profit Ratio
| 0.56 | 0.651 | 0.679 | 0.746 | 0.777 | 0.726 | 0.642 | 0.629 | 0.518 | 0.558 | 0.653 | 0.647 | 0.714 | 0.748 | 0.749 | 0.672 |
| Reseach & Development Expenses
| 12.89 | 14.93 | 14.594 | 10.619 | 12.177 | 13.141 | 14.532 | 14.684 | 70.909 | 11.324 | 12.324 | 9.222 | 2.355 | 5.276 | 2.103 | 3.683 |
| General & Administrative Expenses
| 21.985 | 72.257 | 11.813 | 13.549 | 15.344 | 12.072 | 16.537 | 12.948 | 13.984 | 14.668 | 9.063 | 8.454 | 4.95 | 4.61 | 3.072 | 2.502 |
| Selling & Marketing Expenses
| 49.646 | 102.97 | 126.202 | 189.537 | 167.468 | 205.975 | 184.618 | 104.944 | 35.839 | 16.496 | 18.842 | 11.459 | 6.339 | 5.47 | 5.345 | 11.459 |
| SG&A
| 71.632 | 176.379 | 138.015 | 203.086 | 182.812 | 218.047 | 201.155 | 117.891 | 49.824 | 31.164 | 27.905 | 19.913 | 11.289 | 10.08 | 8.418 | 13.961 |
| Other Expenses
| 119.228 | 0 | 63.178 | 68.968 | 69.66 | 41.486 | -3.125 | 2.213 | 4.22 | 5.076 | -0.44 | 3.497 | 6.625 | 2.517 | 0.615 | 0.913 |
| Operating Expenses
| 203.749 | 219.697 | 215.787 | 282.673 | 264.649 | 272.673 | 283.815 | 182.935 | 179.259 | 73.352 | 54.204 | 41.966 | 26.523 | 23.638 | 15.065 | 20.753 |
| Operating Income
| -106.129 | -36.833 | -24.481 | -42.325 | -53.196 | -13.737 | -90.239 | 0.868 | -389.083 | 57.419 | 69.659 | 75.153 | 73.327 | 77.943 | 71.546 | 38.749 |
| Operating Income Ratio
| -0.609 | -0.156 | -0.089 | -0.132 | -0.197 | -0.04 | -0.268 | 0.004 | -2.681 | 0.249 | 0.432 | 0.502 | 0.566 | 0.584 | 0.634 | 0.439 |
| Total Other Income Expenses Net
| -0.043 | -36.135 | 15.601 | 1.966 | -18.427 | 2.63 | -18.837 | 2.213 | -280.311 | -7.472 | 18.06 | 23.735 | 6.624 | 2.073 | 2.221 | -3.118 |
| Income Before Tax
| -106.172 | -72.968 | -8.881 | -40.359 | -78.78 | 10.517 | -93.364 | 3.081 | -385.077 | 62.281 | 69.109 | 78.629 | 79.951 | 80.017 | 72.161 | 35.893 |
| Income Before Tax Ratio
| -0.609 | -0.309 | -0.032 | -0.126 | -0.292 | 0.03 | -0.277 | 0.012 | -2.653 | 0.27 | 0.429 | 0.526 | 0.617 | 0.599 | 0.639 | 0.407 |
| Income Tax Expense
| 0.097 | -0.992 | -0.385 | 0.45 | 1.17 | 1.488 | -1.216 | 1.752 | 3.334 | 9.602 | 10.176 | 11.857 | 11.952 | 9.605 | 7.931 | 3.786 |
| Net Income
| -78.305 | -50.742 | -8.496 | -40.809 | -79.95 | 9.029 | -69.456 | 6.315 | -388.411 | 52.679 | 58.933 | 66.772 | 67.999 | 70.412 | 64.23 | 32.107 |
| Net Income Ratio
| -0.449 | -0.215 | -0.031 | -0.127 | -0.297 | 0.026 | -0.206 | 0.026 | -2.676 | 0.228 | 0.366 | 0.446 | 0.524 | 0.527 | 0.569 | 0.364 |
| EPS
| -0.19 | -0.12 | -0.021 | -0.1 | -0.2 | 0.022 | -0.17 | 0.02 | -0.96 | 0.13 | 0.15 | 0.17 | 0.19 | 0.23 | 0.21 | 1.9 |
| EPS Diluted
| -0.19 | -0.12 | -0.021 | -0.1 | -0.2 | 0.022 | -0.17 | 0.02 | -0.96 | 0.13 | 0.15 | 0.17 | 0.19 | 0.23 | 0.21 | 1.9 |
| EBITDA
| -43.462 | -9.296 | 60.877 | 24.969 | -10.056 | 81.113 | -19.694 | 60.047 | -346.119 | 90.064 | 70.659 | 67.479 | 73.585 | 80.017 | 76.686 | 43.068 |
| EBITDA Ratio
| -0.249 | -0.039 | 0.222 | 0.078 | -0.037 | 0.234 | -0.058 | 0.243 | -2.385 | 0.39 | 0.438 | 0.451 | 0.568 | 0.599 | 0.679 | 0.488 |